Lv4
410 积分 2025-01-07 加入
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
13天前
已完结
The role of hydrophilic linkers in next-generation antibody-drug conjugates
13天前
已完结
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
13天前
已完结
The future promise of antibody–drug conjugates in extensive-stage small cell lung cancer
21天前
已完结
Stereotactic Radiosurgery (SRS) for Small Cell Lung Cancer (SCLC) brain metastases: a real-world UK tertiary centre experience
21天前
已完结
The future promise of antibody–drug conjugates in extensive-stage small cell lung cancer
21天前
已关闭
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial
22天前
已完结
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial
22天前
已关闭
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
28天前
已完结
Immunotherapy for extensive-stage small cell lung cancer: current status, challenges and future strategies
1个月前
已完结
皖公网安备34019202002308
